Basic information
- CAS
86347-14-0- Standard SMILES
Cc1cccc(C(C)c2cnc[nH]2)c1C- InChIKey
CUHVIMMYOGQXCV-UHFFFAOYSA-N- Molecular formula
- C13H16N2
- Average molar mass
- 200.28 g/mol
- Monoisotopic mass
- 200.13134852
Overview
Medetomidine is a member of imidazoles.
Names & identifiers
- Preferred name
- Medetomidine
- IUPAC
- 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
- English name
- Medetomidine
- Molecular formula
- C13H16N2
- Molecular weight
- 200.28
Names & synonyms
Medetomidine86347-14-0MedetomidinaMedetomidinum5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazoleDomitorMR15E85MQM(+-)-4-(alpha,2,3-trimethylbenzyl)imidazoleDTXSID6048258CHEBI:485525-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazoleRefChem:56412
Show more names
CS-849MedetomidinMedetomidine-D5Medetomidine, BRChlorinated TERT butaneMedetomidine，MedetomidineDexmedetomidine Impurity 38Medetomidine HCl Hydrochloride MedetomidineRAC-4-[1-(2 3-DIMETHYLPHENYL)ETHYL]-1H-I MIDAZOLE
IH-Imidazole, 4(1-(2,3-dimethylphenyl)ethyl)-DTXCID1028233811-718-64-(1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazoleMedetomidinum [Latin]Medetomidina [Spanish]1H-Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-
Database identifiers
- CAS
86347-14-0
Properties
Computed structural properties
- XLogP
- 3.1
- Topological polar surface area
- 28.7 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 15
- Formal charge
- 0
- Complexity
- 205
Experimental & physicochemical properties
DrugsDEA NFLIS-Drug Category -> Analgesics
Animal DrugsFDA approved animal drugs -> Active ingredient
Physicochemical properties
- Boiling point
- 381.9 · 381.9±11.0 °C(Predicted)
- Density
- 1.053 · 1.053
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- Soluble in DMSO
- pka
- 14.29 · 14.29±0.10(Predicted)
- form
- Powder
- color
- White to off-white
- InChI
- InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)
- InChIKey
- CUHVIMMYOGQXCV-UHFFFAOYSA-N
- SMILES
- C1NC(C(C2=CC=CC(C)=C2C)C)=CN=1
- FDA UNII
- 15 E85MQM · MR15E85MQM
- Symbol(GHS)
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Danger
H300: Fatal if swallowed [Danger Acute toxicity, oral]
P260, P261, P264, P270, P271, P273, P284, P301+P316, P304+P340, P308+P316, P316, P319, P320, P321, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Danger
H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]
P260, P264, P270, P271, P273, P284, P301+P316, P304+P340, P316, P320, P321, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Hazard information
Regulatory Information4-(1-(2,3-dimethylphenyl)ethyl-1H-imidazole: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and Categories
Acute Tox. 2 (100%)
Acute toxicity (inhalation) - category 2
Acute Tox. 2
Toxicology
Toxicity Summary
A 2026 "Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management" publication notes that Medetomidine is a racemic mixture of levomedetomidine and the more active dexmedetomidine enantiomers. It can produce prolonged sedation, bradycardia, and biphasic blood pressure effects. Emergency care is complicated since the toxicity persists after naloxone administration. Withdrawal is rapidly progressive, severe, and often resistant to traditional therapies, and the symptoms can begin within four-to-six hours after the last use. The withdrawal symptoms include anxiety, tremor, vomiting, hypertension, tachycardia, and delirium whilethe laboratory findings may include lactic acidosis, hypokalemia, and QTc prolongation.
Chemistry & industry
Pharmacology
ATC CodeQN - Nervous system
MeSH Pharmacological Classification
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
Absorption, Distribution and Excretion
A 2026 "Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management" publication notes that Medetomidine is readily available after intravenous injection and that it can be absorbed through the nasal and buccal mucosa. Extensive first-pass effects limit bioavailability after ingestion.
Applications
DescriptionMedetomidine is a synthetic compound used as a surgical anesthetic and analgesic. It is normally found as its hydrochloride salt, medetomidine hydrochloride. Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer.
UsesAnalgesic (veterinary); sedative (veterinary).
UsesMedetomidine is used in method for synthesizing Medetomidine using 2,3-Dimethylphenylmagnesium Bromide.
Upstream & downstream products
Upstream raw materials
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…